Evidence map›Paper›PMID 31469830›Full record

ArticlePLoS computational biology2019

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA.

Laxmi Parida, Claudia Haferlach, Kahn Rhrissorrakrai, Filippo Utro, Chaya Levovitz, Wolfgang Kern, Niroshan Nadarajah, Sven Twardziok, Stephan Hutter, Manja Meggendorfer and 3 more

Abstract read
In one paragraph

Article in PLoS computational biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Laxmi ParidaIBM Research, Yorktown Heights, New York, United States of America.ORCID 0000-0002-7872-5074
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Kahn RhrissorrakraiIBM Research, Yorktown Heights, New York, United States of America.ORCID 0000-0002-1567-9090
Filippo UtroIBM Research, Yorktown Heights, New York, United States of America.ORCID 0000-0003-3226-7642
Chaya LevovitzIBM Research, Yorktown Heights, New York, United States of America.
Wolfgang KernMLL Munich Leukemia Laboratory, Munich, Germany.
Niroshan NadarajahMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-6486-9675
Sven TwardziokMLL Munich Leukemia Laboratory, Munich, Germany.
Stephan HutterMLL Munich Leukemia Laboratory, Munich, Germany.
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.
Constance BaerMLL Munich Leukemia Laboratory, Munich, Germany.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The confluence of deep sequencing and powerful machine learning is providing an unprecedented peek at the darkest of the dark genomic matter, the non-coding genomic regions lacking any functional annotation. While deep sequencing uncovers rare tumor variants, the heterogeneity of the disease confounds the best of machine learning (ML) algorithms. Here we set out to answer if the dark-matter of the genome encompass signals that can distinguish the fine subtypes of disease that are otherwise genomically indistinguishable. We introduce a novel stochastic regularization, ReVeaL, that empowers ML to discriminate subtle cancer subtypes even from the same 'cell of origin'. Analogous to heritability, implicitly defined on whole genome, we use predictability (F1 score) definable on portions of the genome. In an effort to distinguish cancer subtypes using dark-matter DNA, we applied ReVeaL to a new WGS dataset from 727 patient samples with seven forms of hematological cancers and assessed the predictivity over several genomic regions including genic, non-dark, non-coding, non-genic, and dark. ReVeaL enabled improved discrimination of cancer subtypes for all segments of the genome. The non-genic, non-coding and dark-matter had the highest F1 scores, with dark-matter having the highest level of predictability. Based on ReVeaL's predictability of different genomic regions, dark-matter contains enough signal to significantly discriminate fine subtypes of disease. Hence, the agglomeration of rare variants, even in the hitherto unannotated and ill-understood regions of the genome, may play a substantial role in the disease etiology and deserve much more attention.

Indexed as

AlgorithmsModels, GeneticComputational BiologyDatabases, Nucleic AcidDNA, NeoplasmGene FrequencyGenome, HumanHematologic NeoplasmsHigh-Throughput Nucleotide SequencingHumansMachine LearningPolymorphism, Single NucleotideRNA, UntranslatedStochastic ProcessesWhole Genome SequencingDNA, NeoplasmRNA, Untranslated

Identifiers

PMID31469830
PMCPMC6742441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.